Physician profile
Marshall Teitelbaum
NPI 1336241207
$3,043.87
in general payments reported to CMS, 2019-2025
20 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $117 · 2021: $136 · 2022: $428 · 2023: $347 · 2024: $475 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $631.96 | 2019-2025 | Trintellix |
| Corium, LLC | $481.25 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $429.03 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $294.02 | 2025 | Jornay Pm |
| Lundbeck LLC | $238.10 | 2019-2025 | Rexulti |
| Tris Pharma INC | $194.92 | 2019-2025 | Dyanavel Xr |
| Abbvie INC. | $182.57 | 2021-2022 | |
| Shire North American Group INC | $111.46 | 2019 | |
| Ironshore Pharmaceuticals INC. | $84.61 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.44 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $49.11 | 2024 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $47.86 | 2019 | |
| Vanda Pharmaceuticals INC. | $44.63 | 2025 | Fanapt |
| Adlon Therapeutics L.P. | $39.04 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $37.60 | 2021-2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.22 | 2019-2025 | Spravato |
| Vertical Pharmaceuticals, LLC | $32.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.70 | 2019-2020 | |
| Allergan, INC. | $19.26 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.93 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Teitelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.